Obesity’s explosive growth continues as Q1 deals exceed total 2025 value
BioSpace
Commitments in obesity- and diabetes-focused deals reached $22 billion in the first quarter of 2026--already eclipsing last year's total of $20.3 billion, according to a new J.P.
pharminent
April 16, 2026 (Last updated: April 16, 2026)
BioSpace
Commitments in obesity- and diabetes-focused deals reached $22 billion in the first quarter of 2026–already eclipsing last year’s total of $20.3 billion, according to a new J.P.
